Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Cancer medicine - 1 Sept 2016

Hatch Ace J, Sibley Alexander B, Starr Mark D, Brady J Chris, Jiang Chen, Jia Jingquan, Bowers Daniel L, Pang Herbert, Owzar Kouros, Niedzwiecki Donna, Innocenti Federico, Venook Alan P, Hurwitz Herbert I, Nixon Andrew B

Abstract excerpt

Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cetuximab. Baseline plasma samples from 152 patients were analyzed for six candidate markers [epidermal growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Kaplan-Meier Estimate

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27465221
DOI: 10.1002/cam4.806
PMCID: PMC5055181

Genes

EGF
KRAS
HBEGF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).PMID 27465221Read ↗

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).Semantic proximity Read ↗

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancerSemantic proximity Read ↗

Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.Semantic proximity Read ↗

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationSemantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.Semantic proximity Read ↗

Companion biomarkers: paving the pathway to personalized treatment for cancer.Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Semantic proximity Read ↗

Use of molecular markers for predicting therapy response in cancer patients.Semantic proximity Read ↗

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.